Literature DB >> 12429051

Repeated maternal glucocorticoid administration and the developing liver in fetal sheep.

D M Sloboda1, J P Newnham, J R G Challis.   

Abstract

Prenatal glucocorticoid exposure has been associated with a reduction in birth weight and postnatal alterations in glucose homeostasis and hypothalamic-pituitary-adrenal (HPA) axis function. The mechanisms underlying these responses are unknown, although changes in fetal hepatic development may play an important role. The fetal liver produces key regulators of fuel metabolism and of the developing HPA axis that are altered by glucocorticoids. The local availability of glucocorticoids is regulated, in part, by corticosteroid-binding protein (CBG), glucocorticoid receptors (GR) and by the enzyme 11beta-hydroxysteroid dehydrogenase (11betaHSD), but the effects of maternal glucocorticoid administration on the expression of these genes in the fetal liver are unknown. 11betaHSD1 is the predominant form of this enzyme present in the liver and is responsible for the conversion of cortisone to cortisol. To determine if prenatal glucocorticoid exposure alters fetal hepatic regulation of CBG, 11betaHSD1 and GRs, we treated pregnant ewes with betamethasone (0.5 mg/kg) intramuscularly at 104, 111 and 118 days of gestation (term 150 days). Animals were killed at 125 or 146 days of gestation. Maternal betamethasone administration did not alter mean cord plasma glucose but significantly decreased cord plasma insulin levels (P<0.05) at 125 days of gestation. At 146 days of gestation, cord plasma glucose levels were significantly increased without alterations in insulin levels following maternal betamethasone treatment (P<0.05). Maternal betamethasone administration resulted in a significant increase in fetal hepatic 11betaHSD1 mRNA and protein levels at 125 days of gestation (P<0.05). CBG mRNA levels were significantly elevated over control at 125 days although levels of CBG protein were not significantly different. GR protein levels were not statistically different at either 125 or 146 days of gestation following glucocorticoid administration. These data suggest that prenatal betamethasone exposure in the ovine fetus results in alterations in cord glucose and insulin levels as well as alterations in hepatic 11betaHSD1 mRNA and protein expression. These changes in 11betaHSD1 increase the potential to generate local cortisol from circulating cortisone. We speculate that this could affect expression of glucocorticoid-dependent hepatic enzymes involved with the regulation of glucose production and HPA responsiveness.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429051     DOI: 10.1677/joe.0.1750535

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  4 in total

1.  Fetal exposure to excess glucocorticoid is unlikely to explain the effects of periconceptional undernutrition in sheep.

Authors:  A L Jaquiery; M H Oliver; F H Bloomfield; K L Connor; J R G Challis; J E Harding
Journal:  J Physiol       Date:  2006-02-09       Impact factor: 5.182

2.  Repeated betamethasone treatment of pregnant sheep programs persistent reductions in circulating IGF-I and IGF-binding proteins in progeny.

Authors:  Kathryn L Gatford; Julie A Owens; Shaofu Li; Timothy J M Moss; John P Newnham; John R G Challis; Deborah M Sloboda
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-05-20       Impact factor: 4.310

Review 3.  Metabolic Consequences of Glucocorticoid Exposure before Birth.

Authors:  Abigail L Fowden; Owen R Vaughan; Andrew J Murray; Alison J Forhead
Journal:  Nutrients       Date:  2022-05-30       Impact factor: 6.706

4.  The dilution effect and the importance of selecting the right internal control genes for RT-qPCR: a paradigmatic approach in fetal sheep.

Authors:  Huaisheng Xu; Massimo Bionaz; Deborah M Sloboda; Loreen Ehrlich; Shaofu Li; John P Newnham; Joachim W Dudenhausen; Wolfgang Henrich; Andreas Plagemann; John Rg Challis; Thorsten Braun
Journal:  BMC Res Notes       Date:  2015-02-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.